Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2013 · 10-Q
Revenue$8.03M$8.03M−45.0% vs Q2 2012 Net Income-$4.46M-$4.46MN/M vs Q2 2012 EPS Diluted-$0.10-$0.10N/M vs Q2 2012 Gross Profit$2,150,145−48.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,950,291+9.9% Free Cash Flowderived$1,905,634+11.1% Margins · derivedGross margin26.8%−1.6 pt vs Q2 2012
Operating margin-59.3%−74.5 pt vs Q2 2012
Net margin-55.6%−67.7 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 14, 2013 · 45 d after period end